200572-33-4

Basic information

• Product Name: (3S,4R)-1-BOC-3-HYDROXYMETHYL-4-(4-FLUOROPHENYL)-PIPERIDINE
• Synonyms: (3S,4R)-1-BOC-3-HYDROXYMETHYL-4-(4-FLUOROPHENYL)-PIPERIDINE;(3S,4R)-4-(4-Fluoro-phenyl)-3-hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester;(3S, 4R)-(-)-N-tert-butyloxycarbonyl-4-(4'-fluorophenyl)-3-hydroxyMethylpiperidine;(3S,4R)-4-(4-Fluorophenyl)-3-(hydroxymethyl)-1-piperidinecarboxylic acid tert-butyl ester;(3S-trans)-4-(4-Fluorophenyl)-3-(hydroxymethyl)-1-piperidinecarboxylic acid tert-butyl ester;(3S,4R)-tert-butyl 4-(4-fluorophenyl)-3-(hydroxymethyl)piperidine-1-carboxylate;(3S,4R)-1-​Boc-3-hydroxymethyl-​
• CAS NO: 200572-33-4
• Molecular Formula: C₁₇H₂₄FNO₃
• Molecular Weight: 309.38
• Mol File: 200572-33-4.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 414.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.138
• Storage Temp.: 2-8°C
• PKA: 14.93±0.10(Predicted)
• CAS DataBase Reference: (3S,4R)-1-BOC-3-HYDROXYMETHYL-4-(4-FLUOROPHENYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,4R)-1-BOC-3-HYDROXYMETHYL-4-(4-FLUOROPHENYL)-PIPERIDINE(200572-33-4)
• EPA Substance Registry System: (3S,4R)-1-BOC-3-HYDROXYMETHYL-4-(4-FLUOROPHENYL)-PIPERIDINE(200572-33-4)

Safety Data

• Hazardous Substances Data: 200572-33-4(Hazardous Substances Data)

Usage

General Description

The chemical compound "(3S,4R)-1-BOC-3-HYDROXYMETHYL-4-(4-FLUOROPHENYL)-PIPERIDINE" is a piperidine derivative with a BOC (tert-butoxycarbonyl) protecting group on the nitrogen atom. It has a hydroxymethyl group attached to the third carbon and a 4-fluorophenyl group on the fourth carbon of the piperidine ring. (3S,4R)-1-BOC-3-HYDROXYMETHYL-4-(4-FLUOROPHENYL)-PIPERIDINE is commonly used in organic synthesis and medicinal chemistry as a building block for the preparation of various pharmaceuticals, especially in the development of potential drugs targeting the central nervous system. The stereochemistry of the compound, with a (3S,4R) configuration, is important for its biological activity and interaction with target proteins.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 125224-43-3 (3S,4R)-trans-4-(4-fluorophenyl)-3-hydroxymethylpiperidine 
• 188869-26-3 (3SR,4RS)-trans-4-(4-fluorophenyl)-3-hydroxymethylpiperidine 
• 347-93-3 3-chloro-4'-fluoropropiophenone 
• 392328-32-4 (3S,4R)-(-)-3-acetoxymethyl-N-tert-butyloxycarbonyl-4-(4'-fluorophenyl)piperidine 
• 277744-08-8 (3S,4R)-4-(p-fluorophenyl)-1-[(1R)-2-hydroxy-1-phenylethyl]-3-piperidinemethanol 
• 163438-09-3 (R)-1-Boc-nipecotic acid 
• 349446-96-4 {(3S,4R)-4-(p-fluorophenyl)-3-(hydroxymethyl)-1-[1-(S)-phenylethyl]}piperidine 
• 352-13-6 4-flourophenylmagnesium bromide 

Downstream Products

• 200572-34-5 (3S,4R)-tert-butyl 4-(4-fluorophenyl)-3-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate 
• 923932-19-8 (3S,4R)-4-(4-fluorophenyl)-3-formylpiperidine-1-carboxylic acid tert-butyl ester 
• 2055991-10-9 5-((3S,4R)-1-(tert-butoxycarbonyl)-3-(((tert-butyldimethylsilyl)-oxy)methyl)piperidin-4-yl)-2-fluorobenzoic acid 

Relevant articles and documents

Regio- and Stereoselective Palladium-Catalyzed C(sp3)-H Arylation of Pyrrolidines and Piperidines with C(3) Directing Groups

The selective synthesis of cis-3,4-disubstituted pyrrolidines and piperidines is achieved by a Pd-catalyzed C-H arylation with excellent regio- and stereoselectivity using an aminoquinoline auxiliary at C(3). The arylation conditions are silver free, use a low catalyst loading, and employ inexpensive K2CO3 as a base. Directing group removal is accomplished under new, mild conditions to access amide-, acid-, ester-, and alcohol-containing fragments and building blocks. This C-H arylation protocol enabled a short and stereocontrolled formal synthesis of (-)-paroxetine.

CCR2 MODULATORS

Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I) and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of CCR2 receptors.

PAROXETINE DERIVATIVE

A compound represented by Formula (1), or a pharmacologically acceptable salt thereof retains the principal therapeutic effect of paroxetine and has an improved CYP inhibitory effect: wherein R1 is a hydrogen atom or C1-6 alkyl group